Key result
Intramyocardial injection of CardAPs improved left ventricular function and reduced cardiac remodeling, fibrosis, and hypertrophy in a mouse model of angiotensin II-induced heart failure.
Why the study?
Does intramyocardial injection of CardAPs improve left ventricular function and reduce cardiac remodeling in a mouse model of angiotensin II-induced systolic heart failure?
Population
Mouse model of angiotensin II-induced systolic heart failure, and in vitro models
Comparison
Intramyocardial injection of 200,000… vs Ang II mice without CardAPs (implied)
Design
Preclinical
Authors
Loading...
Supports CardAPs in preclinical HF models; leaves open human translation and trials.
Does intramyocardial injection of CardAPs improve left ventricular function and reduce cardiac remodeling in a mouse model of angiotensin II-induced systolic heart failure?
Human endomyocardial biopsy-derived stromal cells (CardAPs) improve cardiac remodeling and left ventricular function in a mouse model of heart failure, suggesting potential as a cell therapy.
Miteva et al. (2016) studied Angiotensin II-induced systolic heart failure. Cardiac-derived adherent proliferating cells (CardAPs) vs. Control (Ang II mice without CardAPs) was evaluated on Left ventricular function and cardiac remodeling (fibrosis and hypertrophy). Intramyocardial injection of CardAPs improved left ventricular function and reduced cardiac remodeling, fibrosis, and hypertrophy in a mouse model of angiotensin II-induced heart failure.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: